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ABSTRACT
Background: Valid and reliable ischemic stroke subtype determination is crucial for well-powered
multicenter studies. The Causative Classification of Stroke System (CCS, available at
http://ccs.mgh.harvard.edu) is a computerized, evidence-based algorithm that provides both
causative and phenotypic stroke subtypes in a rule-based manner. We determined whether CCS
demonstrates high interrater reliability in order to be useful for international multicenter studies.
Methods: Twenty members of the International Stroke Genetics Consortium from 13 centers
in 8 countries, who were not involved in the design and development of the CCS, indepen-
dently assessed the same 50 consecutive patients with acute ischemic stroke through re-
views of abstracted case summaries. Agreement among ratings was measured by kappa
statistic.
Results: The  value for causative classification was 0.80 (95% confidence interval [CI] 0.78–
0.81) for the 5-subtype, 0.79 (95% CI 0.77–0.80) for the 8-subtype, and 0.70 (95% CI 0.69–
0.71) for the 16-subtype CCS. Correction of a software-related factor that generated ambiguity
improved agreement: 0.81 (95% CI 0.79–0.82) for the 5-subtype, 0.79 (95% CI 0.77–0.80)
for the 8-subtype, and 0.79 (95% CI 0.78–0.80) for the 16-subtype CCS. The  value for pheno-
typic classification was 0.79 (95% CI 0.77–0.82) for supra-aortic large artery atherosclerosis,
0.95 (95% CI 0.93–0.98) for cardioembolism, 0.88 (95% CI 0.85–0.91) for small artery occlu-
sion, and 0.79 (0.76–0.82) for other uncommon causes.
Conclusions: CCS allows classification of stroke subtypes by multiple investigators with high
reliability, supporting its potential for improving stroke classification in multicenter studies and
ensuring accurate means of communication among different researchers, institutions, and eras.
Neurology® 2010;75:1277–1284
GLOSSARY
CCSCausative Classification of Stroke System;CI confidence interval; ISGC International Stroke Genetics Consortium.
Stroke research requires valid and reliable stroke subtype determination, particularly for well-
powered multicenter studies. The Causative Classification of Stroke System (CCS) is a Web-
based, semiautomated, evidence-based classification system constructed upon the simple,
useful, and time-tested Trial of ORG-10172 in Acute Stroke concept of categorizing ischemic
stroke etiology into 5 major subtypes.1,2 CCS (available free for academic use at
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http://ccs.mgh.harvard.edu) is a decision-
making algorithm that incorporates informa-
tion from the diagnostic evaluation of each
patient in a rule-based manner to assign the
most likely causative mechanism. Patients can
be categorized crudely into 1 of 5 subtypes, or,
in a more refined approach, into 8 or even 16
subtypes that specify the level of confidence of
an assignment (table). An internal assessment of
CCS by 2 raters (  0.90)1 and a subsequent
external assessment by 5 raters from 4 US cen-
ters ( 0.86)2 demonstrated excellent reliabil-
ity. In order to ensure its utility in multicenter
clinical studies, we sought to determine multi-
rater reliability of CCS in a more diverse setting
within the network of the International Stroke
Genetics Consortium (ISGC).
METHODS Raters from 13 centers in 8 countries indepen-
dently assessed abstracted data from 50 patients with acute isch-
emic stroke using CCS software. Raters were recruited from
among members of the ISGC through a letter of invitation, and
included 16 stroke neurologists, 2 clinical neuroscientists, 1
stroke fellowship-trained emergency physician, and 1 neurology
resident. Six centers provided ratings by a single rater, 5 centers
provided consensus ratings from paired raters, and 2 centers pro-
vided separate and independent ratings by 2 raters.
Abstracted case summaries were prepared by an experienced
stroke neurologist who did not participate in the assessment pro-
cess. Abstracted data were derived from medical records of 50
consecutive patients presenting to Massachusetts General Hospi-
tal with ischemic stroke during a 1-month period. Abstracted
data included original reports of brain imaging, vascular imag-
ing, cardiac evaluation (EKG, echocardiography), and other lab-
oratory tests. A copy of clinical description of index stroke and
past medical history as reported by the admitting physician was
also included. All data were in English.
Each ISGC rater was provided with prior CCS publica-
tions1,2 and a summary of the operational aspects of the system.
They then completed an interactive online CCS training module
designed to develop consistency among users in identifying crit-
ical data elements for subtype assignment. Raters completed as-
sessments by filling out a standard form for each case vignette,
which included all the activated data entry fields on the classifi-
cation form as well as the final CCS subtype assignment. Raters
were also asked to provide their expert opinion on stroke subtype
independent of their CCS assignment.
Clinical characteristics of the 50 case vignettes have been
described in detail elsewhere.2 All patients had brain imaging
(MRI in 45, CT in 43, both in 37), vascular imaging (CT
angiography in 40, magnetic resonance angiography in 25,
both in 17), and electrocardiography, 41 had echocardiogra-
phy, and 7 had vascular ultrasound studies. Etiologic investi-
gations revealed a high-risk cardiac source in 14 and low-risk
cardiac source in 20 (per CCS criteria), intracranial or ex-
tracranial atherosclerotic stenosis in 14, lacunar infarction in
8, arterial dissection in 3, findings suggestive of primary an-
tiphospholipid syndrome in 2, and angiographic moyamoya
pattern and intracranial aneurysm in 1 patient each. Eleven
patients had multiple potential causes. Etiologic investiga-
tions failed to reveal an etiology in 5 patients.
An updated version of CCS (version 2.0) was used for the
present study (figure 1), which provided phenotypic in addi-
tion to causative subtyping (figure 1B). Phenotypic categories
included supra-aortic large artery atherosclerosis, cardioem-
bolism, small artery occlusion, and other uncommon causes.
There were 4 possible states for supra-aortic large artery ath-
erosclerosis and cardioembolism (major, minor, absent, in-
complete evaluation), 3 for small artery occlusion (major,
absent, incomplete evaluation), and 2 for the other uncom-
mon causes group (major, absent). Possible states for “other
uncommon causes” did not include “incomplete evaluation”
because there was no standard minimum diagnostic evalua-
tion for the group of disorders in this category. A mechanism
was considered major if its potential to cause stroke was high,
minor if it was low, and absent if relevant diagnostic investi-
gations were normal. High-risk sources corresponded to evi-
dent causes and low-risk sources corresponded to possible
causes, as described in detail in prior CCS publications.1,2
Because phenotypic classification depended on only the pres-
ence of a potential source, complex aortic atheroma was
grouped under supra-aortic large artery atherosclerosis in the
phenotypic classification, as opposed to cardioaortic embo-
lism in the causative classification.
Table Causative stroke subtypes according to the Causative Classification
of Stroke System (CCS)a
5 Subtype CCS 8 Subtype CCS 16 Subtype CCS
Supra-aortic large-
artery atherosclerosis
Supra-aortic large-artery
atherosclerosis
Supra-aortic large-artery
atherosclerosis
Evident, probable,
possible
Cardioaortic embolism Cardioaortic embolism Cardioaortic embolism
Evident, probable,
possible
Small-artery occlusion Small-artery occlusion Small-artery occlusion
Evident, probable,
possible
Other uncommon
causes
Other uncommon causes Other uncommon causes
Evident, probable,
possible
Undetermined Undetermined Undetermined
Unknown-cryptogenic
embolism
Unknown-cryptogenic
embolism
Unknown-other cryptogenic Unknown-other cryptogenic
Unclassified Unclassified
Incomplete evaluation Incomplete evaluation
a The CCS assigns causative stroke subtype in 5 major categories (left column). These are
supra-aortic large artery atherosclerosis, cardioaortic embolism, small artery occlusion,
other uncommon causes, and undetermined causes. The undetermined causes group can be
further divided into 4 categories including cryptogenic embolism, other cryptogenic
strokes, incomplete evaluation, and unclassified groups (middle column). This allows classi-
fication of stroke into 8 etiologic subtypes. Each etiologic category in the CCS system is
subdivided based on theweight of evidence as evident, probable, or possible, giving rise to a
16-subtype CCS (right column). An etiology is considered to be evident only if it is the sole
mechanism conforming to one of the major etiologic categories. When there are more than
one evident stroke etiologies, the CCS regularizes assignment to a probable mechanism
based upon the presence of specific stroke characteristics that make onemechanismmore
probable than the others. In the absence of any evident etiology, a search is made for possi-
ble mechanisms that carry low or uncertain risk for stroke.
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Data analyses were performed by investigators uninvolved in
rating case vignettes. Reproducibility of both causative and phe-
notypic subtype assignments was evaluated by the kappa statistic
for multiple raters.3 The sample size (number of case vignettes)
required to achieve a  of 0.75 ( 0.05, power 0.80) was 50
for 15 raters. Kappa values were compared using z test. One-way
analysis of variance was used to assess differences in concordance
for each rater with other raters.
Sources of disagreement among raters were investigated
through systematic comparison of data entry fields (check-
boxes) activated by each rater with a standard template pro-
duced by the data abstractor. Disagreements were classified as
1) failure to enter crucial data elements (for instance, atrial
fibrillation) supplied in case summaries (errors of omission)
and 2) entry of data not reported in the vignette (errors of
substitution). After an initial collection of ratings, refine-
Figure 1 The Causative Classification of Stroke System (CCS) output
The CCS provides subtype assignments in 2 domains: the causative subtype (A) based on a decision-making process that takes into account all
positive and negative test results as well as clinical stroke characteristics and the stroke risks associated with each individual mechanism; and
phenotypic subtype (B) providing a summary of positive test results organized in 4 major categories (assignments were based on an example case
with acute lacunar infarct in the pons, multiple stereotypic lacunar TIAs during the preceding days, patent foramen ovale, mitral annular calcification,
and atheroma causing moderate to severe stenosis at the origin of one of the vertebral arteries). The system allows stroke subtypes along with all the
data entered to be automatically transferred to a database of choice (C), so that the data on test findings and clinical stroke features can be
customized according to the needs of specific research projects and interactions among multiple mechanisms can be explored. Each code repre-
sented by a number-letter combination in (C) corresponds to a data entry field in the automated the CCS software (for instance, 1b for multiple
stereotypic lacunar TIA, 3b for supra-aortic large artery atherosclerosis, 4c for minor cardiac emboli sources).
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ments to the text and to the software were made in order to
eliminate identified sources of these errors.
Standard protocol approvals, registrations, and patient
consents. The study was approved by the local Human Stud-
ies Committee.
RESULTS There were a total of 750 stroke subtype
assignments for 50 case vignettes. Concordance
among ratings was high for the 5-causative subtype
CCS (figure 2). Each rater was concordant with
other raters on an average of 84% (SD 3%) of the
ratings (p  0.837 by analysis of variance). The reli-
ability analysis revealed a  of 0.80 (95% confidence
interval [CI] 0.78–0.81) for the 5-subtype, 0.79
(95% CI 0.77–0.80) for the 8-subtype, and 0.70
(95% CI 0.69–0.71) for the 16-subtype causative
CCS. The kappa across 5 consensus ratings was sim-
ilar to that for 10 single-rater diagnoses (p  0.752
for 5-item CCS, 0.343 for 8-item CCS, and 0.655
for 16-item CCS). Expert global judgment of stroke
subtype was elicited for 10 of the 15 sets of vignettes.
It differed from the 5-causative subtype CCS in 22 of
the 500 ratings (4%).
There was excellent agreement for phenotypic
subtype designation. The  value for phenotypic
classification was 0.79 (0.77–0.82) for supra-aortic
large artery atherosclerosis, 0.95 (0.93–0.98) for car-
dioembolism, 0.88 (0.85–0.91) for small artery oc-
clusion, and 0.79 (0.76–0.82) for other uncommon
causes. One feature of the CCS system is its ability to
assign patients with multiple competing etiologies
into known subtypes. Twenty-two percent of cases in
the current study had more than one etiology. How-
ever, despite this, the size of unclassified category in
15 sets of ratings ranged between only 0% and 8%.
The mean agreement rate between the data ab-
stractor and the study raters on 5-subtype CCS was
88% (95% CI 86%–90%). Rater errors of omission
or substitution that altered the causative subtype as-
signment occurred in 74 case ratings (out of 750 case
ratings); 50 were errors of omission and 24 were er-
rors of substitution. Seventy percent of all errors were
related to data entry fields for imaging evaluation of
the brain and brain vessels, 13% for cardiac evalua-
tion, 10% for clinical evaluation, and 7% for evalua-
tion for other uncommon causes. Interpretation of
imaging findings from reports led to disagreement as
to whether a vascular cutoff was due to embolus or
local atherosclerosis, a vascular stenosis was due to
atherosclerosis or nonocclusive nonatherosclerotic
stenosis, and a small deep infarct described in the
radiology reports was lacunar. Other examples of dif-
ferences in interpretation of the abstracted data in-
cluded whether calcific aortic stenosis indicated
rheumatic aortic valve disease, whether migraine-
related stroke was a diagnosis of exclusion, and
whether prothrombotic abnormalities were the un-
derlying mechanism of stroke in patients with no
other evident cause.
In addition to differences in interpretation of the
abstracted data, one software-related factor contrib-
uted to interobserver disagreement. This was caused
by automatic disabling of data entry fields for cardiac
emboli sources when the field for incomplete cardiac
investigation was activated. This led to inability to
enter cardiac sources revealed by clinical history,
physical examination, or EKG (for instance, atrial
fibrillation) into the system when a rater judged that
cardiac investigations were not complete (for in-
stance, due to absence of echocardiography).
Several refinements and changes in the CCS sys-
tem were therefore made, in order to eliminate rater-
related and software-related sources of disagreement
and accommodate suggestions from participating
raters:
1. Rater-related issues: The CCS offers tool-tips in
the form of pop-up menus to provide more de-
tailed explanations of certain terms and defini-
tions. Revisions and clarifications were made in
these pop-up menus for items where differences
in interpretation occurred. These included a sum-
mary of radiographic features suggestive of ath-
erosclerotic stenosis or occlusion (eccentric
location, calcification, thrombosis, irregular
stump, and occurrence in typical arterial seg-
ments)4 and a statement that isolated calcific aor-
Figure 2 Percentage agreement and 95%confidence intervals for each rater
with other raters for the 5major Causative Classification of
Stroke System subtypes
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tic stenosis was alone not sufficient for the
diagnosis of rheumatic valve disease.
2. Software-related issues: The logic check function
that automatically disabled the data entry fields
for cardiac emboli sources upon activation of the
data field for incomplete cardiac evaluation was
removed. Thus, the system now allows entry of
high-risk or low-risk cardiac sources based on
clinical assessment, EKG, or cardiac examination
even when it is the clinical judgment that cardiac
evaluation is incomplete because of the absence of
echocardiography. This modification is not ex-
pected to affect the interpretation of abstracted
data or terms used in data entry fields. A simula-
tion after modification of this particular function
using raters’ original entries resulted in   0.81
(95% CI 0.79–0.82) for the 5-subtype, 0.79
(95% CI 0.77–0.80) for the 8-subtype, and
0.79 (95% CI 0.78–0.80) for the 16-subtype
causative CCS.
DISCUSSION Etiologic stroke subtype designations
are elemental to clinical investigation of cerebrovas-
cular diseases given the heterogeneity of biologic
mechanisms underlying stroke. It is, therefore, im-
perative to have an easily replicable classification sys-
tem in which all the terms used are sufficiently clear
that they can be used interchangeably by different
investigators. The CCS appears to provide a satisfac-
tory basis for communication among multiple raters.
Taken together with prior internal1 and external US2
reliability studies, the present international study fur-
ther demonstrates that the CCS can be used with
high reliability by multiple raters involved in the
study of stroke.
Interrater reliability is an important measure of
the quality of classification systems. Most systems or
scales currently used in clinical stroke research fail to
achieve excellent reliability. Kappa values reported by
independent investigators at multirater settings range
from 0.42 to 0.68 for TOAST,5-8 0.25 to 0.64 (un-
weighted kappa) for the modified Rankin Scale
score,9-11 and 0.27 to 0.68 for the Bartel Index.12 A
computerized algorithm that used original TOAST
rules revealed a relatively higher  value (0.68, 95%
CI 0.44–0.91) but there were only 2 raters and 20
cases.6 Disagreement is likely to be greater in larger
and unselected cohorts, in cohorts with diverse etiol-
ogies, and at settings where multiple raters (2) are
involved. Deviations from perfect reliability intro-
duce measurement or misclassification error to stroke
research and this, in turn, erodes the efficiency and
power of clinical studies, a critical issue for genetic
research in particular, where the effect sizes of genetic
variants are presumed to be small or moderate.13 De-
pending on the study design and variability in out-
come measure, an improvement in  value from 0.50
to 0.80 will permit a reduction in sample size by up
to 40% to achieve the same study power.14 CCS re-
duces the variance from subjective interpretation of
clinical data by introducing a well-referenced, well-
defined, and evidence-based subtype assignment,
particularly in patients with multiple competing eti-
ologies or incomplete diagnostic investigation. Ap-
plication of the CCS in multicenter studies therefore
offers the potential for increasing the efficiency of
those studies by reducing the sample size needed and,
hence, the cost.
Classification errors generally arise from 3 sources:
the abstracted patient data, the rater, and the input
system. Data-related errors include ambiguities in
the abstracted data (for instance, inconsistencies be-
tween 2 similar tests, such as CT and MRI) and lack
of data that are critical for subtyping (which may
prompt raters to use their best guess). In the current
study, we used a manual, which required documen-
tation of clinical findings and original test report re-
sults in a regularized and standard manner, to guide
the data abstraction process in order to minimize
such potential sources of variance. Reliability can be
artificially high if classification systems are tested in
cohorts that disproportionately consist of subjects
that strongly match a specific category. Such subjects
are unequivocally classified into that category. As
employed in the current study, selection of consecu-
tive patients who harbor a wide spectrum of stroke
etiologies including multiple competing mechanisms
as well as rare and uncertain causes may reduce this
source of bias.
Rater-related errors arise from between-rater dif-
ferences in the classification and assessment of ab-
stracted data. Such variation in expert opinion is
probably to be expected, given that judgments re-
garding etiologic stroke subtype assignment depend
on raters’ experience, knowledge, and understanding
of the classification rules. An inevitable source of
rater-related error is the overlooking of important ab-
stracted information. This is a particular concern in
circumstances where assessment of a cluster of pa-
tients is needed and focus and attention must be
maintained for long periods of time. Another impor-
tant basis for rater-related disagreement noted in the
present study was the unavailability of radiographic
images for visual assessment. Reports of radiographic
images do not always provide the most critical infor-
mation necessary for accurate subtyping. Interpreta-
tion of radiographic images by multiple raters,
however, also introduces variability to research stud-
ies, and its overall impact on the classification results
will have to be tested in a relevant setting.15,16
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CCS offers a number of features to prevent users
from entering inconsistent data. These include input
error checking, automatic disabling, enabling, check-
ing and unchecking of dependent elements, and
tool-tips to provide more detailed explanations of
terms and definitions used in the text. The only
system-related factor for disagreement in the present
study was the inability of system logic functions to
account for differences in expert opinion for the need
for echocardiography for stroke evaluation. High
variance in expert opinion for echocardiography is
not unanticipated because there is no uniform rec-
ommended approach for performance of echocardi-
ography for evaluation of stroke.17,18 CCS requires
echocardiography only if there is clinical suspicion of
cardiac embolism and if clinical history, cardiac ex-
amination, and EKG do not reveal a source. CCS
now allows classification of patients with known
sources of cardiac embolism into relevant subtypes
regardless of the expert opinion for echocardiogra-
phy. The resultant improvement in the reliability
from the simulation analysis suggests that the CCS
can be used in multicenter research with minimal
level of inconsistency.
The CCS offers subtype information in 2 differ-
ent formats: the causative subtype and phenotypic
subtype. Identification of the causative subtype re-
quires integration of multiple aspects of ischemic
stroke evaluation including symptom characteristics,
vascular risk factors, diagnostic test results, response
to treatment, and prognosis. In other words, designa-
tion of the causative subtype requires a decision-
making process. For instance, the diagnosis of small
vessel occlusion requires not only the presence of a
lacunar infarct in a clinically relevant location but
also exclusion of conditions such as dissection, ath-
erosclerosis, vasculitis, or vasospasm of the parent ar-
tery at the origin of the penetrating artery, major
cardiac emboli sources, and other relevant uncom-
mon causes of stroke.
The process of phenotypic subtyping, on the
other hand, does not require any judgment on the
part of the clinician-investigator. Furthermore, there
are no tradeoffs among positive test findings and
thereby inadvertent loss of information. For instance,
in a patient with a lacunar infarction in the pons,
multiple stereotypic lacunar TIAs during the preced-
ing days, patent foramen ovale, and moderate to se-
vere stenosis in the origin of one of the vertebral
arteries, causative CCS subtype is “probable small
vessel occlusion,” whereas phenotypic subtype is
“atherosclerosis  small artery occlusion  cardiac
embolism.” The phenotypic subtyping allows the
study of interactions among etiologic subtypes, pa-
tient selection in large-scale epidemiologic and ge-
netic studies, as well as coding for administrative
purposes. The CCS contains a total of 96 possible
phenotypic combinations. Another algorithm that
has recently been developed a priori for the purpose
of phenotypic subtyping offers 4 subtypes and 5 pos-
sible states for each subtype, resulting in 625 possible
combinations.19 Caution, therefore, should be exercised
in using phenotypic subtypes in research projects with
limited sample size or where the primary purpose is to
assess etiologic stroke subtypes in simultaneous context
with other covariates of interest.
This study does not address the reliability of the
CCS in settings where there are raters from different
professional backgrounds, including, for example,
nurses, residents, general neurologists, and emer-
gency physicians. Reliability analyses were performed
using unweighted kappa. Because 16-item CCS takes
into account the level of confidence in subtype as-
signments, disagreements can occur within each cat-
egory as well as between different categories.
Weighted kappa penalizes disagreements in terms of
their relative importance. Given that between-
category disagreements are generally accepted to be
more serious than intracategory disagreements, the
use of weighted kappa would have resulted in higher
agreement rates compared to the unweighted ap-
proach.20 The use of weighted kappa in multicat-
egory nominal scales, however, requires subjective
weighting of disagreements and this largely depends
on the clinical or research setting where the scale is
being used. The use of abstracted case vignettes gen-
erally inflates kappa values. The reliability of the
CCS might vary in settings where real patients or
actual medical records are used, diagnostic investiga-
tions are cursory, and the causative spectrum of
stroke is different.
The automated CCS offers high reliability for
stroke subtyping with kappa values that compare
very favorably with other classification algorithms.
This demonstrates that classification of stroke sub-
types by investigators from different countries can
achieve sufficient comparability, and suggests the po-
tential utility for CCS in improving stroke classifica-
tion in multicenter trials in which accurate subtyping
is critical.
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Submit a Video to the 2011 Neuro Film Festival
The Neuro Film FestivalSM competition is returning in 2011 to help raise awareness about the need
for neurologic research into treatments and cures for brain disorders. Academy members, their
patients, and their caregivers are invited to submit a video up to five minutes long telling the story
about someone affected by a neurologic disorder. The Grand Prize is $1,000 and a trip to the 2011
Annual Meeting in Hawaii.
Learn more at www.neurofilmfestival.com. Help us show why more brain research is needed to find
cures. Deadline to enter: February 15, 2011.
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